What it is
Ipamorelin is a synthetic pentapeptide, a chain of five amino acids, two of which are not among the twenty found in natural proteins. It binds the growth hormone secretagogue receptor, the receptor for the hormone ghrelin.
Where it came from
Ipamorelin was first described in 1998 by researchers at Novo Nordisk. Earlier compounds acting at the same receptor also triggered other hormonal responses. Ipamorelin was reported as the first to act at the receptor without them, which is what selective means in this context.
What it is used to study
- Binding and selectivity at the growth hormone secretagogue receptor
- Receptor signalling in cell-based systems
- Comparison with ghrelin and with other secretagogue peptides
No effect in people is claimed, and the compound is not sold for human use.
Ipamorelin and the earlier secretagogues
In receptor research that makes ipamorelin the cleaner tool. A response seen with it can be attributed to the one receptor with more confidence than a response seen with the older compounds.
What “CJC-1295 and ipamorelin” refers to
The two names are often searched together. CJC-1295 is a different peptide: a synthetic analogue of growth hormone-releasing hormone, which acts at that hormone's own receptor. Ipamorelin acts at the ghrelin receptor. Because they work through two separate receptors, the pair is used in research to study the two pathways side by side.
They are two compounds, not one, and a product sold under the joint name is a blend of both. We do not stock CJC-1295.
Availability
Ipamorelin is in our range but not yet released. It will be supplied as a pre-mixed vial like the rest, with a batch certificate. Send us a message and we will tell you when it lands.